Table 1. Overview of the different assays reporting complement dependent cytotoxicity assay with rituximab (RTX) in patients with chronic lymphocytic leukemia (CLL), non Hodgkin's lymphoma (NHL), and human B cell lines.
| Cell type (nb) | Number of cells/mL | RTX in μg/mL | Sera (%) | Total incubation time | Detection method | Lysis (%) | Comment | References |
|---|---|---|---|---|---|---|---|---|
| PBMC from CLL (n=33) | 5×104 | 10 μg/ml | 25% | 16h | Alamar | <10% in 58% 10-25% in 21% >25% in 30% |
PBMC not purified B cells (CD20: 65-98%) | [65] |
| NHL and myeloma cell lines (n=3) | 106 | 10 μg/ml | 25% | 12h | Trypan blue and PI | 100% | [75] | |
| CLL (n=5) | 2.5×106 | 20 μg/ml | 50% | 2.5h | PI | Near 0% | [23] | |
| CLL (n=4) and Daudi cell line (n=3) | 5×106 | 10 μg/ml | 50% | 0.25h | PI | CLL: 10% Daudi: 50% |
[76] | |
| CLL (n=11) | 5×105 | 100 μg/ml | 6.25% | 2h | LDH | Near 0% | [48] | |
| EHEB (CLL, n=3) and Raji (n=3) B cell lines | 5×104 | 10 μg/ml | 16.7% | 6h | WST-1 | EHEB: 0% Raji: <20% |
[77] | |
| CLL (n=16) Daudi (n=5) SU-DHL4 (n=5) Raji (n=5) |
Not reported | 10 μg/ml | 20% | 1h to 6h | C51 (CLL) & IP (cell lines) | CLL: 15% Daudi & SU-DHL4: 50-100% Raji: 0% |
[78] | |
| PBMC from CLL (n=6) and NHL (n=6) | 106 | 10 μg/ml | 50% | 30 min | IP | PBMC-CLL: 10% PBMC-NHL: 60% |
PBMC not purified B cells | [79] |
| PBMC-CLL (n=11) Raji (n=4) cell line | 104 | 10 μg/ml | 10% | 90 min | C51 | PBMC-CLL: 10 ± 8% Raji: 41 ± 4% |
PBMC not purified B cells | [80] |
| CLL (n=7) | Not reported | 10 μg/ml | 50% | 30 min | TOPRO-3 | Near 0%, except one (78%) | 1/7 responder | [81] |
| CLL (n=10) and Daudi (n=2) | 107-108 | 100μg/ml | 50% | 15 min to 1 hour | TOPRO-3 and IP | CLL: 10% Daudi: 90% |
CLL cells isolated using Ficoll-Paque | [82] |
Abbreviations: PI: propidium iodide; nb: number of experiments; LDH: lactate dehydrogenase release assay; C51: Chromium-51 release assay; CLL: purified peripheral blood B cells from CLL patients; PBMC: polymorphonuclear B cells from CLL patients.